Nivestim®

Biosimilar medicine authorized by the European Commission

Nivestim®

ACTIVE PRINCIPLE:
Filgastrim

INDICATION:
Neutropenia in the context of oncological processes
Hematopoietic stem cell transplantation

DATE:
08/06/2010

STATUS:
Authorized

MORE INFORMATION

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE